Clinical Trials

Find a Trial

Trial Results

41 protocol(s) meet the specified criteria
IUSCC-0601OPEN TO ACCRUAL
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
PHO-COG-FALLON-AALL05B1OPEN TO ACCRUAL
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
PHO-COG-FALLON-AALL08B1OPEN TO ACCRUAL
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
PHO-COG-FALLON-AALL1131OPEN TO ACCRUAL
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
PHO-COG-FALLON-AALL1231OPEN TO ACCRUAL
AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
PHO-COG-FALLON-AALL1331OPEN TO ACCRUAL
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
PHO-COG-FALLON-AAML1331OPEN TO ACCRUAL
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
PHO-COG-FALLON-ACCL1033OPEN TO ACCRUAL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
PHO-COG-FALLON-ACNS0332OPEN TO ACCRUAL
Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Subjects
PHO-COG-FALLON-ACNS0831OPEN TO ACCRUAL
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
PHO-COG-FALLON-ADVL1622OPEN TO ACCRUAL
ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
PHO-COG-FALLON-AEWS1031OPEN TO ACCRUAL
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
PHO-COG-FALLON-AEWS1221OPEN TO ACCRUAL
Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-AHEP0731OPEN TO ACCRUAL
Treatment of Children with All Stages of Hepatoblastoma
PHO-COG-FALLON-AHOD1331OPEN TO ACCRUAL
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1221OPEN TO ACCRUAL
A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-ANHL12P1OPEN TO ACCRUAL
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
PHO-COG-FALLON-AOST1321OPEN TO ACCRUAL
Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
PHO-COG-FALLON-AOST1421OPEN TO ACCRUAL
A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
PHO-COG-FALLON-AOST1521OPEN TO ACCRUAL
A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-FALLON-ARST1321OPEN TO ACCRUAL
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
PHO-COG-FALLON-D9902OPEN TO ACCRUAL
A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol
PHO-FALLON-COG-AALL15P1OPEN TO ACCRUAL
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ANHL1522OPEN TO ACCRUAL
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-IU-PRADHAN-PACEOPEN TO ACCRUAL
Psychological and Cognitive predictors of Exercise Behavior among Pediatric Cancers
PHO-LILLY-PRADHAN-JGDNOPEN TO ACCRUAL
I5B-MC-JGDN(a) A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE